

Special Issue

The Future of Cancer Immunotherapy: Biomarkers, Tumor Microenvironment, and Precision Medicine

Message from the Guest Editor

Cancer is a complex and diverse disease influenced by genetic, environmental, and lifestyle factors. Recently, there has been a growing emphasis on immunotherapy and personalized medicine as promising strategies for more effectively combating cancer. Current immune checkpoint inhibitors and CAR T-cell therapies face challenges, especially in the treatment of solid tumors. With the advent of high-throughput techniques, both genomics and proteomics have become crucial for identifying mutations that drive tumor initiation and progression, as well as for discovering relevant biomarkers for chemotherapy and immunotherapy. Additionally, proteomic profiling of hematological malignancies and solid tumors will provide deeper insights into the intrinsic and extrinsic factors that shape the tumor microenvironment. By leveraging our current understanding of immunotherapy and conducting genomic and proteomic analyses of cancer patient samples, we can uncover new targets that can aid in the development of novel therapies. Ultimately, this approach aims to enhance life expectancy for cancer patients.

Guest Editor

Dr. Aftab Alam

Department of Immunology, Roswell Park Comprehensive Cancer Center, Elm & Carlton Sts. CGP/BLSC-L5307, Buffalo, NY 14263, USA

Deadline for manuscript submissions

31 May 2026



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/240397

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)